These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

317 related items for PubMed ID: 15330190

  • 1. Evaluation of the clinical significance of HER2 amplification by chromogenic in situ hybridisation in patients with primary breast cancer.
    Dandachi N, Dietze O, Hauser-Kronberger C.
    Anticancer Res; 2004; 24(4):2401-6. PubMed ID: 15330190
    [Abstract] [Full Text] [Related]

  • 2. Analysis of HER2 by chromogenic in situ hybridization and immunohistochemistry in lymph node-negative breast carcinoma: Prognostic relevance.
    Peiró G, Aranda FI, Adrover E, Niveiro M, Alenda C, Payá A, Seguí J.
    Hum Pathol; 2007 Jan; 38(1):26-34. PubMed ID: 17056098
    [Abstract] [Full Text] [Related]

  • 3. Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing.
    Schmidt M, Lewark B, Kohlschmidt N, Glawatz C, Steiner E, Tanner B, Pilch H, Weikel W, Kölbl H, Lehr HA.
    Breast Cancer Res; 2005 Jan; 7(2):R256-66. PubMed ID: 15743506
    [Abstract] [Full Text] [Related]

  • 4. Expression and amplification of Her2, EGFR and cyclin D1 in breast cancer: immunohistochemistry and chromogenic in situ hybridization.
    Cho EY, Choi YL, Han JJ, Kim KM, Oh YL.
    Pathol Int; 2008 Jan; 58(1):17-25. PubMed ID: 18067636
    [Abstract] [Full Text] [Related]

  • 5. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
    Kammori M, Kurabayashi R, Kashio M, Sakamoto A, Yoshimoto M, Amano S, Kaminishi M, Yamada T, Takubo K.
    Oncol Rep; 2008 Mar; 19(3):651-6. PubMed ID: 18288397
    [Abstract] [Full Text] [Related]

  • 6. Prognostic value of HER2 gene amplification detected by chromogenic in situ hybridization (CISH) in metastatic breast cancer.
    Todorović-Raković N, Jovanović D, Nesković-Konstantinović Z, Nikolić-Vukosavljević D.
    Exp Mol Pathol; 2007 Jun; 82(3):262-8. PubMed ID: 17335803
    [Abstract] [Full Text] [Related]

  • 7. Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry.
    Bilous M, Morey A, Armes J, Cummings M, Francis G.
    Pathology; 2006 Apr; 38(2):120-4. PubMed ID: 16581651
    [Abstract] [Full Text] [Related]

  • 8. Expression of HER2 and its association with AP-2 in breast cancer.
    Pellikainen J, Naukkarinen A, Ropponen K, Rummukainen J, Kataja V, Kellokoski J, Eskelinen M, Kosma VM.
    Eur J Cancer; 2004 Jul; 40(10):1485-95. PubMed ID: 15196531
    [Abstract] [Full Text] [Related]

  • 9. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.
    Dressler LG, Berry DA, Broadwater G, Cowan D, Cox K, Griffin S, Miller A, Tse J, Novotny D, Persons DL, Barcos M, Henderson IC, Liu ET, Thor A, Budman D, Muss H, Norton L, Hayes DF.
    J Clin Oncol; 2005 Jul 01; 23(19):4287-97. PubMed ID: 15994142
    [Abstract] [Full Text] [Related]

  • 10. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.
    Vinatzer U, Dampier B, Streubel B, Pacher M, Seewald MJ, Stratowa C, Kaserer K, Schreiber M.
    Clin Cancer Res; 2005 Dec 01; 11(23):8348-57. PubMed ID: 16322295
    [Abstract] [Full Text] [Related]

  • 11. HER2 status in breast cancer determined by IHC and FISH: comparison of the results.
    Mrozkowiak A, Olszewski WP, Piaścik A, Olszewski WT.
    Pol J Pathol; 2004 Dec 01; 55(4):165-71. PubMed ID: 15757204
    [Abstract] [Full Text] [Related]

  • 12. Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma.
    Zhao J, Wu R, Au A, Marquez A, Yu Y, Shi Z.
    Mod Pathol; 2002 Jun 01; 15(6):657-65. PubMed ID: 12065780
    [Abstract] [Full Text] [Related]

  • 13. Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression.
    Umemura S, Takekoshi S, Suzuki Y, Saitoh Y, Tokuda Y, Osamura RY.
    Oncol Rep; 2005 Aug 01; 14(2):337-43. PubMed ID: 16012712
    [Abstract] [Full Text] [Related]

  • 14. Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome.
    Francis GD, Jones MA, Beadle GF, Stein SR.
    Diagn Mol Pathol; 2009 Jun 01; 18(2):88-95. PubMed ID: 19430296
    [Abstract] [Full Text] [Related]

  • 15. Comparison of liquid based cytology and histology for the evaluation of HER-2 status using immunostaining and CISH in breast carcinoma.
    Sartelet H, Lagonotte E, Lorenzato M, Duval I, Lechki C, Rigaud C, Cucherousset J, Durlach A, Graesslin O, Abboud P, Doco-Fenzy M, Quereux C, Costa B, Polette M, Munck JN, Birembaut P.
    J Clin Pathol; 2005 Aug 01; 58(8):864-71. PubMed ID: 16049291
    [Abstract] [Full Text] [Related]

  • 16. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
    Rydén L, Landberg G, Stål O, Nordenskjöld B, Fernö M, Bendahl PO.
    Breast Cancer Res Treat; 2008 May 01; 109(2):351-7. PubMed ID: 17636399
    [Abstract] [Full Text] [Related]

  • 17. HER2 gene status in primary breast cancers and matched distant metastases.
    Tapia C, Savic S, Wagner U, Schönegg R, Novotny H, Grilli B, Herzog M, Barascud AD, Zlobec I, Cathomas G, Terracciano L, Feichter G, Bubendorf L.
    Breast Cancer Res; 2007 May 01; 9(3):R31. PubMed ID: 17511881
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of HER2 gene status in breast cancer by chromogenic in situ hybridization: comparison with immunohistochemistry.
    Kounelis S, Kapranos N, Malamos N, Kouri-Bairaktari E.
    Anticancer Res; 2005 May 01; 25(2A):939-46. PubMed ID: 15868931
    [Abstract] [Full Text] [Related]

  • 19. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
    Korkolis DP, Tsoli E, Fouskakis D, Yiotis J, Koullias GJ, Giannopoulos D, Papalambros E, Nikiteas NI, Spiliopoulou CA, Patsouris E, Asimacopoulos P, Gorgoulis VG.
    Anticancer Res; 2004 May 01; 24(3b):2061-8. PubMed ID: 15274401
    [Abstract] [Full Text] [Related]

  • 20. Her-2/neu oncogene amplification and protein over-expression in interval and screen-detected breast cancers.
    Anttinen J, Kuopio T, Nykanen M, Torkkeli H, Saari U, Juhola M.
    Anticancer Res; 2003 May 01; 23(5b):4213-8. PubMed ID: 14666627
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.